Attitudes toward male fertility control: Results of a multinational survey on four continents

Center for Epidemiology & Health Research Berlin, Berlin, Germany.
Human Reproduction (Impact Factor: 4.57). 03/2005; 20(2):549-56. DOI: 10.1093/humrep/deh574
Source: PubMed


Following extensive research activity to develop an effective agent to control male fertility, such a product may be available for use within approximately 5 years. However, little is known concerning contraceptive knowledge, desires and attitudes of men in different countries, and their acceptance of male fertility control (MFC).
A survey of >9000 males aged 18-50 years was performed in nine countries on four continents in 2002. The objective was to compare, on a cross-cultural basis, the knowledge, attitudes and acceptability of MFC among men and assess their willingness to use such a method.
Between 50 and 83% of the male respondents currently use contraceptive methods, and 55-81.5% reported that both partners participate in selecting the method of contraception employed. Overall acceptance of hormonal MFC was high (>55%), with 28.5-71.4% of survey participants of various nationalities expressing the willingness to use such a method.
While MFC appears to be well accepted overall, the willingness to use this type of contraception varies widely between differing population groups. The specific characteristics and profile of any MFC product will have to be carefully evaluated to accurately assess its acceptance, both by men and their female partners.

Download full-text


Available from: Farid Saad
  • Source
    • "The last reasoning is based on the assumptions that (a) due to availability of safe and effective female contraceptives, male methods are unnecessary; (b) men are unwilling to take contraceptive pills or injections; and (c) men will not adhere to contraceptive drug regimens as careful as do women. These suppositions are in contrast to studies conducted in more than 9000 men in nine countries on four continents (Heinemann et al., 2005). In these studies, men of all nationalities and religions indicated a willingness to use a male contraceptive if a safe, effective product was available. "
    [Show abstract] [Hide abstract]
    ABSTRACT: For a very long time, family planning methods have paid little attention to the needs of men, but instead focused primarily on women. A bulk of contraceptives on the market today is women oriented. Probably, many providers assume that women have the greatest stake and interest as far as family planning is concerned. Worst still, there is a misconception that men are indifferent or even stand in opposition to family planning. The consequences of this long neglect of developing acceptable and reliable male contraceptives in poor developing countries has been lack of or less participation of males in family planning. Recently, it has come apparent that neglecting men in matters of family planning is a losing strategy with adverse consequences for both men and women. As Africa is grappling with rapid population growth, it is now recognized that giving attention to females only can not solve the problem.
    Preview · Article · Jul 2011 · African Journal of Traditional, Complementary and Alternative Medicines
  • Source
    • "One of the main challenges in the development of a male hormonal contraceptive is the need for parenteral administration of testosterone, which has been administered by intramuscular injections or transdermally in experimental contraceptive trials (Brady et al, 2006; Page et al, 2006). When surveyed, however, a majority of men state a preference for an oral form of contraceptive delivery (Martin et al, 2000; Weston et al, 2002; Heinemann et al, 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oral administration of testosterone enanthate (TE) and dutasteride increases serum testosterone and might be useful for male hormonal contraception. To ascertain the contraceptive potential of oral TE and dutasteride by determining the degree of gonadotropin suppression mediated by 4 weeks of oral TE plus dutasteride, 20 healthy young men were randomly assigned to 4 weeks of either 400 mg oral TE twice daily or 800 mg oral TE once daily in a double-blinded, controlled fashion at a single site. All men received 0.5 mg dutasteride daily. Blood for measurement of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, dihydrotesterone (DHT), and estradiol was obtained prior to treatment, weekly during treatment, and 1, 2, 4, 8, 12, 13, 14, 16, 20, and 24 hours after the morning dose on the last day of treatment. FSH was significantly suppressed throughout treatment with 800 mg TE once daily and after 4 weeks of treatment with 400 mg TE twice daily. LH was significantly suppressed after 2 weeks of treatment with 800 mg TE, but not with 400 mg TE. Serum DHT was suppressed and serum estradiol increased during treatment in both groups. High-density lipoprotein cholesterol was suppresed during treatment, but liver function tests, hematocrit, creatinine, mood, and sexual function were unaffected. The administration of 800 mg oral TE daily combined with dutasteride for 28 days significantly suppresses gonadotropins without untoward side effects and might have utility as part of a male hormonal contraceptive regimen.
    Preview · Article · Jan 2008 · Journal of Andrology
  • Source
    • "These results indicate a high degree of acceptance for this new form of male contraception. Most acceptability studies conducted to date have surveyed men about potential characteristics of a hypothetical hormonal contraceptive regimen (Hall, 1971; Balswick, 1972; Keith et al., 1975; Diller and Hembree, 1977; Gough, 1979; Martin et al., 2000; Heinemann et al., 2005a,b). In this study, we interviewed a population undergoing a clinical trial and therefore actually exposed to an experimental contraceptive regimen. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We assessed attitudes towards and acceptability of male hormonal contraception among volunteers participating in a clinical trial of a prototype regimen, consisting of progestin and testosterone injections. After completing screening, eligible men were randomly assigned to the no-treatment group (n = 40) or to receive injections of norethisterone enanthate and testosterone undecanoate or placebo at different intervals (n = 50) according to a blocked randomization list. They underwent self-administered questionnaires. The average age of the participants was approximately 28 years; most were involved in a stable relationship and had no children. Ninety-two percentage of the respondents thought that men and women should share responsibility for contraception and 75% said they would try a hormonal contraceptive if available. At the end of the treatment phase, 66% of the participants said that they would use such a method, and most rated its acceptability very highly; none reported it to be unacceptable. The injections themselves were indicated as the biggest disadvantage. No significant changes in sexual function or mood states were detected among the men who underwent hormone injections. The contraceptive tested in this study was well accepted by the participants over the course of 1 year.
    Preview · Article · Sep 2006 · Human Reproduction
Show more